Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012
GlobalData
January 31, 2012 157 Pages - SKU: GBDT6800807
|
|
Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012
Summary
GlobalData's clinical trial report, “Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2012 provides data on the Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
|
- Introduction
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Report Guidance
- Clinical Trials by Region
- Clinical Trials by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by BRIC Nations
- Clinical Trials by G7 Nations
- Clinical Trials in G7 Nations by Trial Status
- Clinical Trials by E7 Nations
- Clinical Trials in E7 Nations by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Unaccomplished Trials of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer
- Subjects Recruited Over a Period of Time
- Prominent Sponsors
- Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials
- Prominent Drug Comparison
- Clinical Trial Profiles
- Clinical Trial Overview of Top Companies
- Algeta ASA
- Clinical Trial Overview of Algeta ASA
- Bristol-Myers Squibb Company
- Clinical Trial Overview of Bristol-Myers Squibb Company
- Sanofi
- Clinical Trial Overview of Sanofi
- Amgen Inc.
- Clinical Trial Overview of Amgen Inc.
- Johnson & Johnson
- Clinical Trial Overview of Johnson & Johnson
- Oxford BioMedica plc
- Clinical Trial Overview of Oxford BioMedica plc
- Exelixis, Inc.
- Clinical Trial Overview of Exelixis, Inc.
- Astellas Pharma Inc.
- Clinical Trial Overview of Astellas Pharma Inc.
- Novartis AG
- Clinical Trial Overview of Novartis AG
- Ascenta Therapeutics, Inc.
- Clinical Trial Overview of Ascenta Therapeutics, Inc.
- Piedmont Research Center, LLC.
- Clinical Trial Overview of Piedmont Research Center, LLC.
- EntreMed, Inc.
- Clinical Trial Overview of EntreMed, Inc.
- Incyte Corporation
- Clinical Trial Overview of Incyte Corporation
- Celgene Corporation
- Clinical Trial Overview of Celgene Corporation
- Kaiser Permanente
- Clinical Trial Overview of Kaiser Permanente
- Novartis Pharma AG
- Clinical Trial Overview of Novartis Pharma AG
- Enzon Pharmaceuticals, Inc.
- Clinical Trial Overview of Enzon Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Limited
- Clinical Trial Overview of Teva Pharmaceutical Industries Limited
- Pfizer Inc.
- Clinical Trial Overview of Pfizer Inc.
- Merck & Co., Inc.
- Clinical Trial Overview of Merck & Co., Inc.
- Clinical Trial Overview of Top Universities / Institutes / Hospitals
- European Organization for Research and Treatment of Cancer
- Clinical Trial Overview of European Organization for Research and Treatment of Cancer
- Fox Chase Cancer Center
- Clinical Trial Overview of Fox Chase Cancer Center
- The University of Texas M. D. Anderson Cancer Center
- Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center
- University of California, San Francisco
- Clinical Trial Overview of University of California, San Francisco
- British Columbia Cancer Agency
- Clinical Trial Overview of British Columbia Cancer Agency
- Duke University
- Clinical Trial Overview of Duke University
- Albert Einstein College of Medicine of Yeshiva University
- Clinical Trial Overview of Albert Einstein College of Medicine of Yeshiva University
- New York University School of Medicine
- Clinical Trial Overview of New York University School of Medicine
- Alberta Health Services
- Clinical Trial Overview of Alberta Health Services
- Kurume University
- Clinical Trial Overview of Kurume University
- Barbara Ann Karmanos Cancer Institute
- Clinical Trial Overview of Barbara Ann Karmanos Cancer Institute
- Sheba Medical Center
- Clinical Trial Overview of Sheba Medical Center
- UCSF Helen Diller Family Comprehensive Cancer Center
- Clinical Trial Overview of UCSF Helen Diller Family Comprehensive Cancer Center
- Sidney Kimmel Comprehensive Cancer Center
- Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center
- Dana-Farber Cancer Institute
- Clinical Trial Overview of Dana-Farber Cancer Institute
- Roswell Park Cancer Institute
- Clinical Trial Overview of Roswell Park Cancer Institute
- University of Washington
- Clinical Trial Overview of University of Washington
- Medical University of Vienna
- Clinical Trial Overview of Medical University of Vienna
- The University of Iowa
- Clinical Trial Overview of The University of Iowa
- Assistance Publique - Hopitaux de Paris
- Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
- Five Key Clinical Profiles
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About GlobalData
- Contact Us
- Disclaimer
- Source
- List of Tables
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Zone, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, BRIC Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, G7 Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, E7 Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Phase, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Phase 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Withdrawn Clinical Trials, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Terminated Clinical Trials, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Algeta ASA, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Oxford BioMedica plc, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Exelixis, Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Astellas Pharma Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Ascenta Therapeutics, Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Piedmont Research Center, LLC., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by EntreMed, Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Incyte Corporation, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Kaiser Permanente, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis Pharma AG, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Enzon Pharmaceuticals, Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Teva Pharmaceutical Industries Limited, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Fox Chase Cancer Center, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by British Columbia Cancer Agency, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Duke University, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Albert Einstein College of Medicine of Yeshiva University, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by New York University School of Medicine, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Alberta Health Services, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Kurume University, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Barbara Ann Karmanos Cancer Institute, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sheba Medical Center, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by UCSF Helen Diller Family Comprehensive Cancer Center, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Dana-Farber Cancer Institute, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Medical University of Vienna, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Iowa, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2012*
- List of Figures
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Zone (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Top Countries, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, BRIC Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, G7 Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, G7 Countries, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, E7 Countries (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, E7 Countries, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Phase (%), 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials In Progress by Phase, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Trial Status, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2005-2010
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2012*
- Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Clinical Trials by Prominent Drugs, 2012*
- GlobalData Methodology
Share this report
Other tasks Related Markets Men's Health Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
